Trial Profile
A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2022
Price :
$35
*
At a glance
- Drugs Vandefitemcel (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- Acronyms STEMTRA
- Sponsors SanBio
- 26 Apr 2022 Final Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 05 Apr 2022 Positive results from the one-year analysis published in the SanBio Media Release.
- 24 Mar 2022 According to a SanBio media release, final analysis results of the STEMTRA study including data up to 48 weeks will be announced and presented by Dr. Peter McAllister at the 2022 Annual Meeting of the American Academy of Neurology